logo

For the Inventor, By the Inventor

Encinitas, CA, United States of America

Vitukudi Narayanaiyengar Balaji

This inventor holds 19 USPTO granted patents, primarily in Sulfonamide Compounds. Top assignees: Texas Biotechnology Corporation, Immunopharmaceutics, Inc., Encysive Pharmaceuticals, Inc.. Active years: 1994-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vitukudi Narayanaiyengar Balaji. Retrieved from https://idiyas.com/inventor/vitukudi-narayanaiyengar-balaji

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 19

% Patents Active = 94.7

Average Co-Inventor Count = 4.3

ph-index = 13

Forward Citations = 601(Granted Patents)


Location History:

  • San Diego, CA (US) (1996)
  • Encinitas, CA (US) (1994 - 2003)
  • Bengaluru, IN (2003)

Company Filing History:

goldMedal12 out of 37 
 
Texas Biotechnology Corporation
 patents
silverMedal3 out of 3 
 
Immunopharmaceutics, Inc.
 patents
bronzeMedal1 out of 9 
 
Encysive Pharmaceuticals, Inc.
 patents
4. 3 out of 834,601 
Other
 patents

Years Active: 1994-2003

Loading Chart...
Areas of Expertise:
Sulfonamides
Endothelin Modulation
Drug Design
Biphenylsulfonamides
Cyclic Peptides
Thienyl Compounds
Furyl Compounds
Pyrrolyl Compounds
Phenyl Derivatives
Computer Simulation
Rational Drug Design
Substituted Compounds
19 patents (USPTO):Explore Patents
1. 6613804 - Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin (2003-09-02),
2. 6541498 - Benzenesulfonamides and the use thereof to modulate the activity of endothelin (2003-04-01),
3. 6376523 - Benzenesulfonamides and the use thereof to modulate the activity of endothelin (2002-04-23),
4. 6342610 - N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin (2002-01-29),
5. 6331637 - N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin (2001-12-18),
6. 6265428 - Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin (2001-07-24),
7. 6030991 - Benzenesulfonamides and the use thereof to modulate the activity of (2000-02-29),
8. 5977117 - Substituted phenyl compounds and derivatives thereof that modulate the (1999-11-02),
9. 5962490 - Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that (1999-10-05),
10. 5736509 - Cyclic peptide surface feature mimics of endothelin (1998-04-07),
11. 5612895 - Method of rational drug design based on ab initio computer simulation of (1997-03-18),
12. 5594021 - Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that (1997-01-14),
13. 5591761 - Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof (1997-01-07),
14. 5579250 - Method of rational drug design based on AB initio computer simulation of (1996-11-26),
15. 5571821 - Sulfonamides and derivatives thereof that modulate the activity of (1996-11-05),

Title: Exploring the Innovations of Vitukudi Narayanaiyengar Balaji

Introduction

Vitukudi Narayanaiyengar Balaji is a notable inventor based in Encinitas, California, who has made significant contributions to the field of pharmaceuticals with a focus on endothelin-mediated disorders. With a remarkable portfolio of 19 patents, his work addresses critical health issues through innovative chemical compounds.

Latest Patents

Among Balaji's latest patents are formulations related to biphenylsulfonamides and derivatives that modulate the activity of endothelin, a family of peptides involved in various physiological processes. His patents describe bicyclic and tricyclic carbon or heterocyclic ring biphenylsulfonamides that inhibit the binding of endothelin peptides to their receptors. Through these inventions, methods of treating endothelin-mediated disorders, including inflammatory diseases such as asthma, are outlined by administering effective amounts of sulfonamides or their prodrugs.

Additionally, Balaji's work includes patents on benzenesulfonamides, particularly N-(5-isoxazolyl) and N-(3-isoxazolyl) compounds. These patents provide methods for modulating endothelin activity and highlight the potential of N-isoxzolyl-4-biphenylsulfonamides as endothelin receptor B antagonists.

Career Highlights

Throughout his career, Balaji has been associated with Texas Biotechnology Corporation, contributing his expertise to the development of innovative therapeutic solutions. His vast experience in the industry has positioned him as an influential figure in pharmaceutical research and development.

Collaborations

Balaji’s collaborative efforts with esteemed professionals such as Ming Fai Chan and Adam Kois have further expanded his research scope, fostering advancements in the understanding and treatment of endothelin-related conditions.

Conclusion

Vitukudi Narayanaiyengar Balaji represents a significant force in the intersection of science and innovation. His extensive patent portfolio reflects his dedication to addressing pressing medical challenges through novel chemical solutions. As his research progresses, Balaji's contributions are poised to impact the treatment landscape for various diseases significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…